|
Non-Small Cell Lung Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
|
29754146 |
2018 |
|
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
|
29754146 |
2018 |
|
Hydrocephalus
|
0.200 |
Biomarker
|
disease |
MGD |
A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting.
|
9553039 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, rescue assay revealed E2F5 to be essential for the tumor suppressive effects of miR-32.
|
31173286 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, miR-1179 overexpression could also inhibit tumor growth in vivo by suppressing the expression of E2F5.
|
29859832 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of Drp1 with E2F5-mimetic peptide for inducing Drp1 mitochondrial localization enhanced ceramide-mediated mitophagy and led to tumor suppression in HPV-negative HNSCC-derived xenograft tumors in response to cisplatin in SCID mice.
|
28606997 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Collectively, our findings indicate that FOXN3 functions as a tumor suppressor in HCC by downregulating the expression of E2F5.
|
27259277 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Co-localization of E2F5 with pSMAD3L in the nuclei of tumor and PC3 cells indicated a functional interface between the proteins.
|
26919443 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
pRb2/p130 is a key tumor suppressor, whose oncosuppressive activity has mainly been attributed to its ability to negatively regulate cell cycle by interacting with the E2F4 and E2F5 transcription factors.
|
25205458 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The enforced expression of miR-17, a major member from this family, reduced the expression of the tumor suppressor genes E2F5, TP53INP1, TRIM8 and ZBTB4, and protected cells from serum-free-induced apoptosis (P ≤ 0.05).
|
22343732 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, distinct MIN-tumor-associated DNA amplifications were detected for E2F5 (8p22-q21.3), GARP (11q13.5-q14), ATM (11q22.3), KAL (Xp22.3), and XIST (Xq13.2) as well as DNA deletions for RAF1 (3p25), DCC (18q21.3), and KEN (21q tel). aCGH revealed distinct DNA copy number changes of oncogenes and tumor suppressor genes in CIN- and MIN-type sporadic colorectal carcinomas.
|
17143621 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study provides a new insight in the crucial role of E2F cross-talk, especially the role of the inhibiting transcription factors E2F4 and E2F5, in the tumor biology of cancer and its possible usefulness as targets in anti-cancer therapy.
|
16721044 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
5-kb E2F5 transcript was also detected in some tumors and tumor cell lines.
|
10738311 |
2000 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In addition, knockdown of E2F5 and PFTK1 mimicked the tumor-suppressive effects of miR-1-3p overexpression on PCa progression.
|
30185212 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
E2F5 was a direct target of miR-132, and downregulation of E2F5 caused by upregulation of miR-132 may contribute to the tumorigenesis of prostate cancer.
|
29393367 |
2018 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
E2F5 was a direct target of miR-132, and downregulation of E2F5 caused by upregulation of miR-132 may contribute to the tumorigenesis of prostate cancer.
|
29393367 |
2018 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In addition, knockdown of E2F5 and PFTK1 mimicked the tumor-suppressive effects of miR-1-3p overexpression on PCa progression.
|
30185212 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Further, E2F5 overexpression could also nullify the effect on cell proliferation, migration and invasion in pancreatic cancer cells.
|
29859832 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
miR-154-5p may play an important role as an inhibitor of proliferation, migration and invasion of PCa by targeting E2F5 in PCa cell lines.
|
27074041 |
2017 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
miR-154-5p may play an important role as an inhibitor of proliferation, migration and invasion of PCa by targeting E2F5 in PCa cell lines.
|
27074041 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Reintroduction of E2F5 without 3'-untranslated region reversed the inhibitory effects of miR-613 on cell proliferation and invasion.
|
28351331 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The effects of forced miR-154-5p expression or E2F transcription factor 5 (E2F5) knockdown on PCa cells were evaluated by cell proliferation, flow cytometry, cell migration and invasion assays as well as by Western blot analysis.
|
27074041 |
2017 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
|
26919443 |
2016 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
|
26919443 |
2016 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Reintroduction of FMNL2 or E2F5 without 3'UTR region reversed the inhibitory effects of miR-34a on cell proliferation and invasion.
|
26103003 |
2015 |